New Frontiers in the Treatment and Management of Alzheimer’s Disease: Expert Perspectives on the Role of Emerging Therapies

A continuing medical education activity provided by NAMCP and AAMCN

This activity is an archive of the live session from the 2021 Spring Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from July 1, 2021 – August 1, 2022

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by an educational grant from

Alzheimer’s disease is the most common form of dementia, affecting an estimated 5 million people in the United States. It is a cognitive disorder that includes behavioral impairment that interferes with social and occupational functioning. Over time the disease destroys large areas of the brain, resulting in cellular loss and dysfunction, a gradual loss of memory, problems with reasoning or judgment, disorientation, difficulty in learning, loss of language skills, and decline in the ability to perform routine tasks. Although not all memory loss indicates Alzheimer’s disease, one in ten people over 65 years of age, and over half of those over 85 have Alzheimer’s disease. By the year 2050, over 15 million Americans may be affected with the disease. Alzheimer’s disease care costs $172 billion annually in the United States alone. However, advances in the science underlying Alzheimer’s are emerging at a rapid rate with a large number of potential agents undergoing clinical trials.

Currently, an autopsy or brain biopsy is the only way to make a definitive diagnosis of Alzheimer’s disease. Diagnosing Alzheimer's requires careful medical evaluation, including medical history, mental status testing, physical and neurological exam, blood tests and brain imaging. PCPs are increasingly called on to provide care for cognitively impaired individuals, playing critical roles in detecting early symptoms of dementia, communicating with patients and caregivers about the disease, coordinating with specialists on multimodal therapeutic plans, and following up to tailor treatment, minimize complications, and head off medical crises. The importance of early diagnosis cannot be understated. As the use of biomarkers continues to grow, the potential for catching Alzheimer’s disease even earlier is crucial to improving outcomes. While there is no cure for Alzheimer’s disease or a way to stop or slow its progression, there are pharmacologic and non-pharmacologic options that may help treat symptoms.

Upon completion of this activity, participants will be able to:

  • Assess recent advances in clinical data and guidelines for diagnosis and treatment of dementia

  • Discuss optimal diagnostic testing strategies for early detection and evaluation of Alzheimer's disease and related dementias

  • Evaluate the safety and efficacy data of new and emerging treatment therapies, including a close look at disease modifying therapies

  • Analyze investigational treatment strategies and neurodegenerative alterations in patients with Alzheimer’s disease

  • Examine the multidisciplinary roles in managing dementia and the interventions for supporting caregivers


Faculty: Marc Agronin, MD
Senior Vice President for Behavioral Health
Miami Jewish Health


Dr. Agronin serves as a consultant for Biogen, Lilly and Otsuka. He has served on the speaker's bureau for Allergan. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no financial relationships with ineligible companies to disclose.
Jeremy Williams has no financial relationships with ineligible companies to disclose.
Jacqueline Cole, RN, MS, CMCN has no financial relationships with ineligible companies to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by an educational grant from

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue